The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > BUSINESS
BUSINESS
- Japan Pharma Market Levels Off in July-September: IMS
November 13, 2014
- 90 Pharma Companies Join Forces to Reduce CO2 Emissions; Aiming at 23% Reduction by FY2020
November 13, 2014
- CMIC Holdings, UDG Healthcare Collaborate in CSO, CMO Businesses
November 13, 2014
- Avigan Could Clinch Overseas Approval for Ebola Early Next Year: Fujifilm Official
November 13, 2014
- Fujifilm Sees Healthcare as Growth Engine in Next 3 Years, yet No New Drug Debut until FY2018
November 12, 2014
- Generic Makers Back on Growth Track in First Half of FY2014
November 12, 2014
- Shionogi Lodges Complaint against Tax Reassessment over ViiV Deal
November 12, 2014
- Daiichi Sankyo Completes Tender Offer to Acquire Ambit Biosciences
November 12, 2014
- Takeda, GE Healthcare Forge Alliance for Hepatic Diseases
November 12, 2014
- Ethical Drug Sales Down 0.2% in September Owing to Long-Listed Drug Sales Decline: Crecon Report
November 12, 2014
- BIKEN Begins Clinical Trial of Varicella Vaccine for Herpes Zoster
November 12, 2014
- Dermatology Firm Maruho Eyes US Product Rollout in Next 3 Years
November 12, 2014
- Santen Extending Geographic Reach in Europe after Merck Asset Transfer
November 11, 2014
- Kowa Looks to Triple Eye Drug Business with Glanatec
November 11, 2014
- Germany Designates Eisai’s Antiepileptic Drug Fycompa as Reference Price Drug
November 11, 2014
- AstraZeneca Taps Foreign Doctors to Speak on Forxiga Use Abroad
November 11, 2014
- Nichi-Iko Aims for 300 Million Yen Second Half Sales for Generics Launched in December
November 10, 2014
- Takeda Files Suit in US Claiming Infringement of Its Patents for Gout Treatment Colcrys
November 10, 2014
- MTPC, J&J Collaborate to Promote Educational Activities for Diabetes
November 10, 2014
- Feburic Grabs Top Slot for GP Market in September “Mind Share” Ranking
November 10, 2014
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…